If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Filing of eight patent applications

1 Aug 2022 07:00

RNS Number : 3245U
e-Therapeutics plc
01 August 2022
 

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Filing of eight patent applications on

proprietary GalNAc-siRNA technology and target related innovation

 

 

London, UK, 1 August 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, today announced the filing of eight further patent applications in the United States ("US") to protect innovation arising from e-therapeutics' proprietary GalNAc-siRNA technology.

 

The Company uses its proprietary GalNAc-siRNA technology to silence any gene in liver hepatocytes. As announced on 26 October 2021, e-therapeutics' GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action. 

 

The eight patent applications relate to innovation arising from the Company's work on its pipeline of pre-clinical siRNA candidates in several therapeutic areas and include innovation around novel target ideas and associated disease-relevant biology identified using the Company's computational platform, novel siRNA therapeutics and novel siRNA chemistries associated with such siRNA therapeutics. 

 

This news follows e-therapeutics' announcement on 4 May 2022, as part of its year-end results statement, that eleven patent applications had been filed to protect proprietary and novel GalNAc-siRNA silencing construct designs.

 

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"This second announcement of significant patent filings within three months demonstrates fast and meaningful scientific and technological progress. It also reflects our commitment to protecting the Company's proprietary innovation, which forms a critical part of our strategy as we continue to make material steps in developing a computationally driven in-house pipeline of highly differentiated RNAi medicines at speed. Our computational platform not only affords us an important advantage in drug discovery, but also in IP strategy, and we are leveraging this position in our patent applications."

 

 

 

Enquiries:

e-therapeutics plc

 

Ali Mortazavi, CEO

James Chandler, VP IR & Communications

Tel: +44 (0)20 4551 8888

www.etherapeutics.co.uk

 

 

 

 

SP Angel Corporate Finance LLP

 

Tel: +44(0)20 3470 0470

Nominated Adviser and Broker

 

Matthew Johnson/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and biological insight to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease- and modality-agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to capture and interrogate human disease complexity more fully.

 

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and screening. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVEDIIAFIF
Date   Source Headline
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding
25th Jun 20143:57 pmRNSHolding(s) in Company
20th Jun 20144:22 pmRNSHolding(s) in Company
20th Jun 20141:41 pmRNSHolding(s) in Company
18th Jun 20146:14 pmRNSAdditional Listing
30th May 20147:00 amRNSAnnual Financial Report and Notice of AGM
22nd May 20144:15 pmRNSIssue of Equity
12th May 20147:00 amRNSFull year results
8th May 20147:00 amBUSe-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial
2nd May 20144:46 pmRNSHolding(s) in Company
2nd May 20144:42 pmRNSHolding(s) in Company
2nd May 20144:29 pmRNSHolding(s) in Company
25th Apr 20147:00 amRNSNotice of Results
7th Apr 20141:07 pmRNSDirectorate Change
7th Apr 201411:46 amRNSDirectorate Change
31st Mar 20146:56 amBUSe-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours
26th Mar 20147:00 amBUSe-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial
10th Feb 20147:02 amBUSe-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers
24th Jan 20147:00 amBUSTemporary halt of recruitment into ETS2101 cancer trials because of drug supply issue - Patients already being treated will continue to be dosed
9th Jan 20142:34 pmRNSAdditional Listing
7th Jan 20147:00 amBUSStatement re e-Therapeutics provides update on ETS2101 phase I trial in brain cancer
31st Oct 20137:00 amBUSResearch Update
16th Oct 20137:00 amBUSHalf-yearly Report
30th Sep 20134:45 pmRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSNotice of Interim Results
6th Aug 201312:43 pmRNSAdditional Listing
1st Aug 20134:53 pmRNSDirector/PDMR Shareholding
30th Jul 20133:30 pmRNSDirector/PDMR Shareholding
25th Jul 201311:09 amRNSResult of AGM
24th Jul 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jul 20134:41 pmRNSDirector/PDMR Shareholding
1st Jul 20139:00 amRNSNotice of AGM and Annual Report
21st Jun 20137:00 amRNSProactive Investors One2One Forum 26th Manchester
18th Jun 20134:11 pmRNSManchester One2One Investors Forum - June 26
14th May 20137:00 amBUSPreliminary results for the year ended 31 January 2013
18th Apr 20137:00 amRNSNotice of Results
4th Apr 20135:18 pmRNSDirector/PDMR Shareholding
25th Mar 201310:44 amRNSHolding(s) in Company
18th Mar 20135:19 pmRNSIssue of Equity
13th Mar 20136:19 pmRNSHolding(s) in Company
6th Mar 201310:01 amRNSHolding(s) in Company
5th Mar 20135:44 pmRNSHolding(s) in Company
4th Mar 20133:31 pmRNSHolding(s) in Company
4th Mar 20133:23 pmRNSDirector/PDMR Shareholding
4th Mar 20132:56 pmRNSHolding(s) in Company
1st Mar 20137:00 amRNSCompletion of the Placings
28th Feb 201312:01 pmRNSCompletion of First Placing / Issue of Equity
27th Feb 201310:01 amRNSResult of General Meeting / Issue of Equity
22nd Feb 20132:51 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.